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Context. The current literature suggests that perinatal palliative care (PPC) programs should be comprehensive, initiated early,
and integrative. So far there have been very few publications on the subject of home-based PC of newborns and neonates. Most
publications focus on hospital-based care, mainly in the neonatal intensive care units. Objective. To describe the neonates and
infants who received home-based palliative care in Lodz Region between 2005 and 2011.Methods. A retrospective review ofmedical
records. Results. 53 neonates and infants were admitted to a home hospice in Lodz Region between 2005 and 2011. In general,
they are a growing group of patients referred to palliative care. Congenital diseases (41%) were the primary diagnoses; out of 53
patients 16 died, 20 were discharged home, and 17 stayed under hospice care until 2011.Themost common cause of death (56%) was
cardiac insufficiency. Neurological symptoms (72%) and dysphagia (58%) were the most common clinical problems. The majority
of children (45%) had a feeding tube inserted and were oxygen dependent (45%); 39 families received psychological care and 31
social supports.Conclusions. For terminally ill neonates and infants, perinatal palliative care is an optionwhich improves the quality
of their lives and provides the family with an opportunity to say goodbye.
1. Introduction
Constant development and improvement of prenatal diag-
nosis present new opportunities in the field of perinatal
palliative care (PPC) [1, 2]. The current literature suggests
that PPC programs may be comprehensive, initiated early,
and integrative [2]. PPC is understood as a constant care of
a family during pregnancy and delivery and after the birth of
its child and includes the care of newborns and infants [2–4].
In Poland, palliative care (PC) for children has been
providedmainly by specialized pediatric palliative home-care
teams. Such a home-based model of care is called “home
hospice” [5]. Currently in Poland (38 million inhabitants),
there are almost 40 pediatric home hospices, and in the years
2000–2010 the number of children treated in home hospices
had increasedmore than fivefold [6]. Planned physician visits
take place once a fortnight, and planned nurse visits twice a
week. Patients and parents have a round-the-clock access to
telephone consultation service, and intervention visits are a
standard procedure in case of a patient’s health deterioration.
Visits of psychologists, social workers, physiotherapists, and
hospital chaplains are planned according to individual needs
of each family. PC is free of charge—all children have
governmental health insurance. Allmedical equipment is lent
to the families free of charge.
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The Home Hospice for Children of Lodz Region
(HHChLR) is a specialized pediatric palliative home care
team, in this paper referred to as “home hospice.” HHChLR
was founded in 2005. Since then it has had a total of over 180
children under its care and taken the fourth place in Poland in
terms of the number of treated children. In the Lodz Region
(over 2,5 million inhabitants with 471,000 children), there is
only one other pediatric home hospice and HHChLR looks
after 80% of children eligible for PC.
So far there have been very fewpublications on the subject
of home-based PC of newborns and neonates [2, 4, 7]. Most
publications focus on hospital-based care, mainly in neonatal
intensive care units [8, 9].
The aim of this study is to describe the population of the
neonates and infants who received home-based PC provided
by HHChLR.
2. Material and Methods
We conducted retrospective reviews of medical records to
obtain data about all patients aged 0–12 months under the
care of HHChLR between January 1, 2005, and December 31,
2011.
The following variables were abstracted from the med-
ical records: (1) demographic information (patient age and
gender); (2) clinical information (principal diagnosis that
triggered original referral to palliative care, main clinical
symptoms, medications, and medical technology utilized);
and (3) follow-up information (death or discharge from the
hospice, time of death, location of death, duration of PC at
home, and social and psychological support).
The principal diagnoses were divided into 4 groups
according to International Statistical Classification of Dis-
eases and Related Health Problems—10th Revision (ICD-
10) [10]: (1) congenital malformations, deformations, and
chromosomal abnormalities (CM); (2) certain conditions
originating in the perinatal period (CCPP); (3) diseases of
the nervous system (DNS); (4) metabolic diseases (MD).The
location of death was categorized as home and hospital. The
duration of care was calculated from the date of admission
to the home hospice till the date of death or discharge from
the home hospice or—for those patients who remained under
home hospice care—until December 31, 2011. The study was
approved by the Ethics Committee of the Medical University
of Lodz (RNN/137/10/KE).
3. Statistical Analysis
Using the final database, descriptive statistics were used
to describe patient characteristics. Data on the number of
children (aged 0–19 years) living in the Lodz Region was
downloaded from the databank of the Central Statistical
Office of Poland [11]. The prevalence of children referred to
the palliative care at home in Lodz Region was computed and
converted to a denominator of 100,000. A linear trend was
calculated using Pearson correlation coefficient for preva-
lence ratios of children aged 0–12 months and older than
12 months requiring PC in the respective years of the study.
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Figure 1: Prevalence of children referred to the palliative care at
home in Lodz Region (years 2005–2011).
To determine differences between the groups in continuous
variables, the Kruskal-Wallis test was used. Nominal vari-
ables were compared between the groups using a test for
proportion with multicomparison Bonferroni correction. All
statistical analyses were performed using STATISTICA for
Windows release 8.0 software. Value of 𝑃 < 0.05 was used
as a definition of the statistical significance.
4. Results
In the study period, 53 children aged 0–12 months (29% of
all 184 patients) were admitted to HHChLR, and they are a
growing group of patients referred to PC (Figure 1). At the
time of admission to the home hospice the patients were aged
between 24 and 357 days (median: 128; 25–75 percentile: 62–
219,5); 51% of them were male.
Themost common principal diagnoses (41%) in the study
group were CM; the longest duration of PC was observed in
patients with DNS. Patients’ characteristics are presented in
Figure 2 and Table 1.
Out of the 53 patients admitted to the hospice, 16 died, 20
were discharged from home hospice and 17 were still under
home hospice, care on December 31, 2011. The patients who
died had been under home hospice care for between 10 and
751 days before their death (median: 136,5; 25–75 percentile:
78,6–253); ten patients died at home, 6 in a hospital. The
highest mortality was observed among patients with MD but
patients with CM died significantly earlier than those with
other diagnoses (Figure 3).Themost common causes of death
were cardiac insufficiency (56%), respiratory insufficiency
(16%), hemorrhage (16%), and cardiorespiratory insufficiency
(12%).The location and causes of death did not differ between
the groups of patients.
The most common reason for being discharged from the
home hospice was stabilization of health status. Discharged
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Table 1: Diagnoses spanned a wide spectrum of patients’ diseases and patients’ characteristics.
Patients’ groups according to
diagnoses N (%)
Age of admission
in days median
(25–75 percentile)
Deaths Discharges
Patients remaining
under hospice care on
December 31, 2011.
N
Age of death in
days median
(25–75 percentile)
N
Duration of care in
days median
(25–75 percentile)
N
Duration of care in
days median
(25–75 percentile)
Total 53 (100) 128 (62–219,5) 16 248 (138–528) 20 125,5 (70,5–187,3) 17 264 (161–833,5)
Congenital malformations,
deformations, and
chromosomal abnormalities
22 (41) 82 (38,5–191,8) 9 150,5 (110,3–242,8) 6 218 (104,3–404,5) 7 264 (170–549)
Certain conditions originating
in the perinatal period 14 (26) 139 (119,3–204,5) 2 700,0405,0 10 111 (58,75–144,3) 2 52 (52–52)
Diseases of the nervous system 11 (21) 91 (55–314) 2 762 (637–887) 4 157,5 (41–186,3) 5 814 (226,5–1346)
Metabolic diseases 6 (12) 187 (139,8–249) 3 283 (65–528) — — 3 344 (23–1921)
Congenital 
malformations;
Trisomy 13 and 18 (5; 4; 0; 1)
CNS malformations (4; 3; 0; 1)
Multiple congenital malformations (3; 0; 0; 3)
Pierre Robin syndrome (2; 0; 2; 0)
Epidermolysis bullosa (2; 0; 2; 0)
Wolf-Hirschhorn syndrome (2; 1; 1; 0)
(4; 1; 1; 2)
Zellweger syndrome (3; 3; 0; 0)
Nonketotic (2; 0; 0; 2)
Deficiency of adenylosuccinate lyase (1; 0; 0; 1)
Encephalopathy Bronchopulmonary dysplasia  (14; 2; 10; 2)
Others
n = 22 (41%)
Metabolic
diseases;
n = 6 (12%)
Diseases of the
nervous system;
n = 11 (21%)
Certain conditions
originating in the
perinatal period;
n = 14 (26%)
(11; 2; 4; 5) 
Hyperglycinemia
Figure 2: Diagnoses spanned awide spectrumof patients’ diseases. Numbers in parentheses indicate the total number of patients; the number
of patients who died; the number of discharged patients; the number of patients who stayed under hospice care till December 31, 2011.
children suffered mainly from bronchopulmonary dysplasia
and congenital diseases. The duration of PC at home among
patients who were discharged varied from 10 to 727 days
(median: 125,5; 25–75 percentile: 70,5–187,3).
The most frequent clinical problems included neurolog-
ical symptoms (72%) and dysphagia (58%)—Figure 4. The
incidence of such symptoms was significantly lower among
patients with CCPP than in the other groups (𝑃 < 0.001).
A high percentage of the infants (45%) had a feeding
tube (naso- or orogastric) inserted and were permanently or
periodically oxygen dependent (45%) (Figure 4).
The subjects had extensive medication profiles: the mean
number of medications per patient was 8.4 (SD 4.9), with a
range from 3 to 26medications—Figure 5. Palliative sedation,
provided at home by subcutaneous access, was indicated
in 7 patients, including 3 in the end stage of life and 4
during the hospice care. In all cases, midazolam was used
as the primary medication; in 4 cases morphine and in 1
case buprenorphine were added to the treatment. Metoclo-
pramide and hyoscine were used in 3 cases as adjuvants
during sedation before death. There were no differences
in medications prescribed between patients from different
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Figure 3: Age of death among the groups of study patients (ex-
pressed as median and 25–75 percentile). CM: congenital mal-
formations, deformations, and chromosomal abnormalities. CCPP:
certain conditions originating in the perinatal period. DNS: diseases
of the nervous system. MD: metabolic diseases.
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Figure 4: Clinical symptoms andmedical technology used by study
patients.
groups of principal diagnoses. Nevertheless, children with
CCPP used no opioids, and a different profile of antiepileptic
drugs (AEDs) was observed between the groups—Table 2.
According to the standard of care inHHChLR at least one
visit of a psychologist and social worker took place in each
family. Out of 53 families 39 received permanent psycholog-
ical care and 31 social supports. Ten families of children who
died participated in a support group for bereaved parents.
5. Discussion
Transition to PC is the most difficult decision for the parents
of a child with life limiting illness. This decision is usually
connected with many questions and fears, especially when
care is planned as a home-based model. This model of PC
0 10 20 30 40
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Number of patients
Inhaled Beta-mimetics
Figure 5: Groups of drugs used by study patients. GCSs: Glucocor-
ticosteroids. NSAIDs: Nonsteroidal anti-inflammatory drugs. PPIs:
Proton-pump inhibitors.
should be promoted as the most suitable for both children
and their families, as well as cheaper than the inpatient
model of care. This opinion corresponds with international
standards which recommend home-based medical care with
strong emphasis on psychological and social support [12, 13].
The largest so far retrospective studies conducted to date, in
the United States [14] and in Great Britain [15], describe a
significant change over time in the place wheremost children
with a life limiting illness die. Earlier research conducted by
HHChLR indicated a strong need for that type of care in
Lodz Region, especially in the field of PPC [16]. We showed
that in the years 2000–2004 almost 90% of children with
chromosomal aberrations died in hospitals [16]. The current
presented analysis shows that every third patient referred to
HHChLR between 2005 and 2011 was under the age of 12
months. Additionally, we observed that the youngest patients
were a growing group of those referred to PC at home.
These results are consistent with nationwide observations,
which may indicate a better cooperation between hospices
and neonatal and prenatal diagnostic centers [6].
The ideal model of PC for children prenatally diagnosed
with lethal defects includes hospice care during pregnancy.
Polish law allows pregnant women whose fetus has been
diagnosed with a lethal defect to perform abortion up to
22–24 weeks of the pregnancy gestation. However, abortion
is a challenging decision and hard to discuss in Poland, a
country where 90% of the population are declared catholics.
From the experience ofHHChLR, it seems that those children
with lethal defects who survive after birth are very often
in need of invasive treatment and frequently die in the
hospital. Epidemiological data from the Lodz Region in 2010
showed that 101 children died before 12 months of age,
including 80 newborns, and the present study showed that
the youngest patient referred to home PC was 24 days old.
Home based PPC is therefore an alternative for those families
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Table 2: Profile of antiepileptic drugs used by study patients.
Antiepileptic drugs
Groups of the principal diagnoses
Congenital malformations,
deformations, and chromosomal
abnormalities (𝑛 = 22)
Certain conditions
originating in the perinatal
period (𝑛 = 14)
Diseases of the
nervous system
(𝑛 = 11)
Metabolic
diseases
(𝑛 = 6)
Total
(𝑛 = 53)
n % n % n % n % n %
Phenobarbital 12 54 3 21 9 82 5 83 25 47
Diazepam 11 50 1 7 10 91 4 66 28 53
Vigabatrin — — 1 7 6 54 3 50 10 19
Topiramate 1 4 1 7 3 27 3 50 8 15
Lamotrigine — — — — 1 9 1 16 2 4
Valproic acid 2 8 1 7 5 45 4 66 12 23
Clonazepam 2 8 — — — — 2 32 4 8
Zonisamide — — — — — — 1 16 1 2
Clomethiazole — — — — — — 1 16 1 2
Nitrazepam — — — — 1 9 — — 1 2
who decide not to terminate the pregnancy, and it protects the
child from suffering and risky medical interventions [17, 18].
Multidisciplinary care allows the family to say goodbye to
their terminally ill baby in a peaceful environment.
The above described model of care in case of an unsuc-
cessful prenatal diagnosis is currently being discussed in
the Lodz Region. The HHChLR team is promoting this
model through specialised training offered to pediatricians
and nurses. That work has been inspired by the current
experience ofHHChLR—all the familieswho took part in this
research received postnatal PC notwithstanding the prenatal
diagnosis. None of the families had been informed during the
pregnancy about the possibility of PPC.
The analysis of patients referred to the HHChLR before
their first birthday in terms of the primary diagnosis confirms
the observations of other authors regarding the criteria for PC
[3, 4, 7, 19, 20]. Some uncertainties in thosematters can derive
from the fact that there are cases of patients discharged from
the home hospice due to the improvement of their clinical
condition. Discharged children had been diagnosed mainly
with bronchopulmonary dysplasia or had been waiting for
surgical correction of congenital malformations. Very often
home hospice care is the only alternative to the hospital
care for those children, hence the referral. Such a procedure
reflects some recommendations [1, 2]. The experience of
HHChLR indicates that professional, constant home care
improves the patients’ general well-being and stabilizes their
condition. The discharge from the home hospice is possible
after the parents have been trained, family doctors informed
about the child’s condition, and the family provided with
specialized medical equipment indispensable to the child.
The present data show that the longest PC was provided
for patients with neurological diseases and the primary
clinical symptoms were neurological signs and dysphagia.
Given the profile of the patients, these results should not
be surprising and are consistent with observations of other
researchers [3, 4, 19].
It is known that the occurrence of neurological symptoms
is not limited only to the diseases of nervous system, and
unfortunately ICD-10 does not give a full scope of those
diseases qualifying for PC. Most metabolic diseases are
in fact neurometabolic; many patients with chromosomal
defects and congenital malformations display pathology of
their neurological systems [21, 22]. Thus, the first year of
life is the period with the highest incidence of epilepsy
in children and adolescents. It is worth noting that ICD-
10 classifies epilepsy as a separate disease where in fact it
is a range of somatic, psychic, and vegetative symptoms
resulting from many metabolic and morphological changes
in the brain. In the present study different profiles of AEDs
were observed between the groups. Among the patients with
epilepsy, those in palliative care are more often patients with
drug-refractory epilepsy. The causes of intractable epilepsy
are neurometabolic disease, disorders of brain development,
and specific epileptic encephalopathies [23]. Additionally, the
situation of infants is disadvantageous especially because of
the small number of registered AEDs. Thus, the control of
drug-resistant epilepsy in this population is often inadequate,
and requires a rational and appropriate polytherapy, often
with the use of old generation AEDs [24, 25]. The care of
patients with a chronic and often progressive neurological
disease is complex and requires a multilevel approach. To
provide the patient and his/her family with adequate care and
support, the most appropriate form of care seems to be home
pediatric PC.
Dysphagia caused by the motility abnormalities of the
upper part of digestive system in children with severe CNS
damage can occur anytime during a child’s life. During the
infant stage, those patients with chromosomal abnormali-
ties, congenial CNS malformations, and severe HIE present
abnormalities of sucking and swallowing reflexes [26, 27].
Total enteral feeding with the appropriate management of
other symptoms leads to a fast improvement of the children’s
condition, which confirms the diagnosis and builds the
parents’ trust. The present study showed that 45% of patients
needed nutritional support before the age of one. The type
of support is conditioned above all by the diagnosis and
prognosis as well as the length of life [27]. In addition, the
type ofmedical technology used reflects the profile of patients
referred to PPC. Almost half of the patients presented oxygen
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dependency, and one in ten patients were provided with
tracheostomy or ventriculo-peritoneal shunt. The youngest
patients of HHChLR did not have central venous catheters
and noninvasive ventilation.
Some findings connected with the medications profile
warrant emphasis and discussion. A particular issue is the
use of palliative sedation at home. Continuous palliative
sedation (CPS) is usually implemented at the end of life,
but the definition of CPS does not preclude its application
earlier if persistent symptoms intolerable for the patient
are observed. In the present study, both situations were an
indication for this procedure. Although there is no shortage
of data on the reasons for and implementation of CPS in adult
patients, the number of studies in the pediatric population
is small [28–30]. Our observations support the view that
CPS can be utilized at any age, including newborns and
infants, taking into account distinct pharmacokinetic and
pharmacodynamic properties of sedative drugs. Seven years
of HHChLR experience (CPS provided in over 40 patients—
unpublished data) indicate that palliative sedation can be
safely used in the patient’s home, on condition that the
guardians are instructed how to operate the equipment,
supply the drugs and monitor sedation.
PC includes the bereavement phase of the family life as
well [1, 2], and our observations confirm the need for relevant
support.
The limitations of the present study include the lack
of comparison with other models of PC since home-based
care is dominant in Poland. There is also a lack of similar
research in Poland. Another limitation is the small number
of participants. However, the study describes 7 years of
experience with the home-based model of PPC provided
by HHChLR, which looks after 80% of families referred to
palliative care in the Lodz Region; therefore, our results can
be considered as fairly reliable and representative for the
entire region.
6. Conclusions
In cases where the prognosis remains uncertain, PPC is
an option which improves the quality of patients’ life and
provides the family with an opportunity to say goodbye to
them in a peaceful way.The results of the present study are in
accordance with the suggestions in the current literature that
PPC programs should be comprehensive, initiated early and
integrative.
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